scPharmaceuticals Inc. (2SX.F)
| Previous Close | 4.3600 |
| Open | 4.4600 |
| Bid | 4.1400 x 0 |
| Ask | 4.2400 x 0 |
| Day's Range | 4.3200 - 4.4600 |
| 52 Week Range | 4.0000 - 10.9000 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 155.755M |
| Beta (5Y Monthly) | 0.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3200 |
| Earnings Date | May 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.67 |
GlobeNewswirescPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Management to host conference call and webcast at 4:30 p.m. ETBURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results
- GlobeNewswire
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and
Simply Wall St.Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%
scPharmaceuticals Inc. ( NASDAQ:SCPH ) shareholders might be concerned after seeing the share price drop 23% in the...
